PSKH-1 ribozymes

Details PSKH-1 ribozymes PSKH-1 ribozymes

1996-09-18

1999-01-05

LeGuyader, John L.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 231, 536 232, 435 6, 435 9131, 435375, C07H 2104, C12Q 168

Patent

active

058564632

ABSTRACT:
Disclosed is a purified full-length cDNA molecule encoding putative serine kinase enzyme (PSKH-1), and the expression of the cDNA in a recombinant host cell to produce substantially purified PSKH-1, per se. Inactivation of PSKH-1 pre-MRNA or PSKH-1 mRNA halts DNA synthesis and cell division. Also disclosed are ribozymes capable of cleaving PSKH-1 pre-mRNA or mRNA and thus deactivating PSKH-1 translation. Ribozymes of the hammerhead and hairpin motifs, and various compositions containing same, are also disclosed. The ribozymes compositions are used in the treatment of mammalian patients suffering from diseases or medical conditions characterized by abnormal cell proliferation or growth such as cancer and various non-malignant diseases or medical conditions such as autoimmune diseases, allograft rejection and atherosclerosis.

REFERENCES:
patent: 5144019 (1992-09-01), Rossi et al.
patent: 5246921 (1993-09-01), Reddy et al.
patent: 5272262 (1993-12-01), Rossi et al.
patent: 5436330 (1995-07-01), Taira et al.
patent: 5441880 (1995-08-01), Beach et al.
patent: 5443962 (1995-08-01), Draetta et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5496698 (1996-03-01), Draper et al.
patent: 5527895 (1996-06-01), Hampel et al.
Christoffersen et al. Ribozymes as Human Therapeutic Agents. J. Med. Chem. 38(12): 2023-2037, Jun. 1995.
Gewirtz et al. Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on its Promise. Proc. Natl. Acad. Sci. USA 93 3161-3163, Apr. 1996.
Gura. Antisense has Growing Pains. Science 270: 575-577, Oct. 1995.
Stull et al. Antigens, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects. 12(4): 465-482, Apr. 1995.
Larsen et al., Hum. Mol. Gen. 2(10):1589-1595 (1995).
Hanks, Proc. Natl. Acad. Sci. USA 84:388-392 (1987).
Kim et al., Proc. Natl. Acad. Sci. USA 84:8788-8792 (1987).
Haseloff et al., Nature 334:585-591 (1988).
Cech, JAMA 260(20):3030-3034 (1988).
Jefferies et al., Nucl. Acad. Res. 1989, 17, 1371.
Cech et al., Nature 372:39-40 (1994).
Uhlenbeck, Nature 328:596-600 (1987).
Forster et al., Cell 50:9-16 (1987).
Pley et al., Nature 372:68-74 (1994).
Tuschl et al., Science 266:785-789 (1994).
Pyle, Science 261:709-714 (1993).
Hampel et al., 28 Biochemistry 4929, 1989.
Hampel et al., 18 Nucleic Acid research 299, 1990.
Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987).
Pachuk et al., Proc. Annu. Meet Am Assoc. Cancer Res. 34:A2313 (1993) (Abstract Only).
Leopold et al., Blood (United States)85:2162-70 (1995) (Abstract Only).
Vertosick et al., J. Neurooncol (Netherlands) 19(2):97-103 (1994) (Abstract Only).
Baier et al., Mol. Immunol. 31(12):923-32 (1994) (Abstract Only).

Affiliated with

Also associated with

Rating

PSKH-1 ribozymes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PSKH-1 ribozymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PSKH-1 ribozymes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-863522